The team identified gene expression patterns that can determine how severe a patient's systemic sclerosis is and if treatment has been effective.
Based on genetic patterns in thousands of individuals with primary sclerosing cholangitis, researchers identified four new risk loci and explored ties to IBD.
The company said this week that is has raised $36 million in funding, as it continues efforts to develop its Maverick platform for rapid testing in doctors' offices.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
The studies looked at applications including predicting disease progression, guiding drug tapering, and identifying patients at risk of related conditions.
The firm brought in total revenues of $177.5 million in the first quarter, compared to $183.5 million in Q1 2016, beating the consensus Wall Street estimate.
In colon tissue samples from individuals with Crohn's disease, researchers discovered either colon- or ileum-like expression features.
A University of Colorado School of Medicine-led team reported 23 new loci associated with vitiligo susceptibility.
The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.
The company said this study marks the first time circulating RNA has been concretely linked to IFN dysregulation in lupus patients.
After reporting FY2016 revenues below market expectations, Myriad discussed plans to increase sales of Prolaris, Vectra DA, EndoPredict, GeneSight, and myChoice HRD.
Despite the historical adoption and reimbursement challenges for PGx testing firms, Myriad said it would try to achieve value-based pricing for Assurex's GeneSight test.
The firm is investing in studies that use its multiplex microarray platform to monitor lupus disease activity and traumatic brain injury response.
A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.
The meta-analysis drew on studies conducted in both European and Chinese populations, and hinted at why lupus may be more common among East Asians.
Firalis is developing an assay based on HTG's EdgeSeq platform to identify rheumatoid arthritis patients likely to respond to anti-TNF-alpha therapies.
An international research team studied how genetic factors control immune cell response to pathogens in healthy individuals.
Certain bacterial species appear more common in gut microbiomes of individuals with MS, coinciding with inflammation-related gene expression in host blood.
The collaboration will use Transplant Genomics' TruGraf test for post-kidney transplant monitoring to try to personalize immunosuppression therapies.
The company now offers three CE-marked autoantibody assays — for BICD2, Scl70, and CENP-B — that can be used for clinical management of the condition.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.